Skip to main content

IDWeek 2022 Main banner

Tweets by IDWeek 2022

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

371 Views

Poster Session: COVID-19: Treatment

1160 - Treatment-Emergent Viral Variants in the Phase 3 TACKLE Trial Investigating Efficacy and Safety of AZD7442 (Tixagevimab/Cilgavimab) for the Treatment of Mild to Moderate COVID-19 in Adults

Friday, October 21, 2022

12:15 PM – 1:30 PM US ET

Location: Hall B + C

The ePoster content is available to users who are logged in.<br><br>Please click the login button at the top right corner and then come back here to use this button.

Presenting Author(s)

Gustavo H. Kijak, PharmD PhD (he/him/his)

Principal Scientist
AstraZeneca
Gaithersburg, Maryland, United States

Co-Author(s)

BA

Bahar Ahani, BSC

AstraZeneca
Gaithersburg, Maryland, United States
DA

Douglas Arbetter, MPH

AstraZeneca
Waltham, Massachusetts, United States
TB

Tyler Brady, MS

AstraZeneca
Gaithersburg, Maryland, United States
FC

Fernando Chuecos, BS

AstraZeneca
Barcelona, Catalonia, Spain
VG

Vancheswaran Gopalakrishnan, PhD

AstraZeneca
Gaithersburg, Maryland, United States
TR

Tiffany L. Roe, B.S.

AstraZeneca
Gaithersburg, Maryland, United States
NS

Nicolette Schuko, MS

AstraZeneca
Gaithersburg, Maryland, United States
FH

F.D. Richard Hobbs, FMedSci

Head of Primary Care
University of Oxford
Oxford, England, United Kingdom
FP

Francisco Padilla, MD

Centro de Investigación en Cardiología y Metabolismo
Guadalajara, Jalisco, Mexico
EK

Elizabeth J. Kelly, PhD

AstraZeneca
Gaithersburg, Maryland, United States
HM

Hugh Montgomery, MD

University College London
London, England, United Kingdom
KS

Katie Streicher, PhD

AstraZeneca
Gaithersburg, Maryland, United States